BackCassava Sciences- Warrants (15/11/2024) Overview

Cassava Sciences- Warrants (15/11/2024) Total Liabilities

Cassava Sciences- Warrants (15/11/2024)'s total liabilities is $40M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$40.29M
15.01% YoYΔ $-7.12M vs prior year quarter

Peer trimmed avg / median

Loading

Cassava Sciences- Warrants (15/11/2024) Total Liabilities History

Loading

Cassava Sciences- Warrants (15/11/2024) vs. peers: Total Liabilities Comparison

Loading

Cassava Sciences- Warrants (15/11/2024) Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Cassava Sciences- Warrants (15/11/2024) (SAVAW) FAQ

Cassava Sciences- Warrants (15/11/2024)'s total liabilities stands at $40M as of June 2026. That compares with $47M in the prior-year period — down 15.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Cassava Sciences- Warrants (15/11/2024) reported $40M in total liabilities versus $47M a year earlier — a 15.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $47M in the prior-year period — down 15.0% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Cassava Sciences- Warrants (15/11/2024)'s total liabilities evolved across reporting periods, while the comparison chart places SAVAW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Cassava Sciences- Warrants (15/11/2024)'s reading of $40M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.